Dry Granulation Precedes Direct Tablet Press Feed for Heat-Labile API

Direct compression of the API powder is excluded at production scale because the uncompacted material exhibits a Hausner ratio above 1.34 and a Carr index above 25% as determined per USP General Chapter <1174> powder flow methodology. The spray-dried API powder has a bulk density of 0.32–0.38 g/mL and tapped density of 0.48–0.55 g/mL, which produces unacceptable die-fill variation on rotary tablet presses operating above 40 rpm. Slugging on a mechanical press at 30–40 kN compaction force or roller compaction at 12–18 kN/cm roll pressure converts the powder into flakes that are subsequently milled through a 1.0 mm screen aperture. Roller compaction with a 200 mm diameter roll and a 0.8 mm screen aperture yields granules with a D50 between 250–450 μm, as verified by laser diffraction per USP <786>. The dry granulation route is selected over wet granulation because the API is thermally labile and partially hydrolyzes when exposed to aqueous binder solutions at temperatures above 40 °C for more than 30 minutes.

The granule blend is formulated as follows: API 20.0% w/w, microcrystalline cellulose (Avicel PH-102) 55.0% w/w, lactose monohydrate 20.0% w/w, crospovidone 4.0% w/w, and magnesium stearate 1.0% w/w. Blend uniformity testing per USP <905> must show an acceptance value not exceeding 15.0 with all individual values within ±5.0% of target. Blend hold time should not exceed 72 hours at 25 °C / 60% RH; beyond this interval moisture uptake above 0.2% w/w measurably reduces tablet tensile strength. Tableting is performed on a 16-station rotary press with pre-compression force set at 3–5 kN and main compression at 8–14 kN, producing 6.0 mm diameter tablets with hardness between 50–80 N. Production-scale observations document capping failures at compression speeds above 60 rpm when pre-compression is omitted, and edge chipping when die bore lubrication falls below 0.5% w/w magnesium stearate. Disintegration per USP <701> without discs must be complete within 15 minutes in 900 mL purified water at 37 ± 2 °C. The tablet cores are film-coated with an HPMC/PEG 3350 aqueous system at 2.5–3.0% w/w weight gain; spray rate is maintained at 8–12 g/min with inlet air at 65–70 °C. The finished tablet is a bronchodilator dosage form intended for companion animal respiratory therapy. Stability protocols follow ICH Q1A(R2): long-term 25 °C / 60% RH and intermediate 30 °C / 65% RH conditions. Published data for this specific API in veterinary tablet stability beyond 24 months remains limited; ongoing commitment batches per VICH GL1 are required to extend shelf life assignment.

For parenteral administration in cattle and swine with acute respiratory distress, the API is formulated as a sterile solution or lyophilized cake for reconstitution. Where aqueous solubility of the API powder falls below 5 mg/mL at 25 °C in purified water, co-solvent systems containing propylene glycol and PEG 400 at 20–40% v/v are required to achieve target concentrations of 25–100 mg/mL. Terminal steam sterilization at 121 °C for 15 minutes with F₀ ≥ 12 minutes is preferred over aseptic filtration when the API demonstrates thermal stability in the chosen buffer system. Batch records from lyophilization lines indicate that fill volume accuracy within ±1.0% requires peristaltic pump recalibration at intervals not exceeding 4 hours. When terminal sterilization is not feasible due to degradation products exceeding VICH GL18 identification thresholds, aseptic processing through 0.22 μm PVDF cartridge filters in a Grade A/ISO 5 environment is employed. Filter integrity testing per ASTM F838-20 must be performed before and after each sterilizing filtration batch. Bacterial endotoxin limits are set at < 0.5 EU/mg per USP <85>, and sterility testing per USP <71> uses fluid thioglycollate medium and soybean-casein digest medium incubated for 14 days. The solution pH is buffered to 6.5–7.5 with citrate or phosphate buffers, and tonicity is adjusted to 280–320 mOsm/kg. Packaging in Type I borosilicate vials per Ph. Eur. 3.2.1 with chlorobutyl rubber stoppers under nitrogen overlay is mandatory because the API is susceptible to oxidative degradation when dissolved oxygen exceeds 0.5 ppm. Production bottlenecks are documented at the filling stage: nozzle clogging due to API crystallization occurs when room temperature falls below 15 °C, and solution viscosity rising above 30 cP at concentrations above 100 mg/mL reduces peristaltic pump throughput by 15–20%. Terminal injection products are administered intravenously or intramuscularly at volumes of 1–10 mL depending on species and body weight; label claims must align with 21 CFR Part 514 and EU Regulation 2019/6 Annex II. Incompatibility with rubber stoppers containing high free-sulfur levels has been observed as visible particulate formation after 6 months at 25 °C; stopper compatibility must be confirmed via extraction studies per USP <381>.

What Limits Powder Flow Through Multidose Capsule Filling Nozzles?

The milled API as-received exhibits cohesive behavior because the D50 particle size lies between 25–40 μm and the specific surface area exceeds 3.5 m²/g by BET nitrogen adsorption; interparticle van der Waals forces dominate gravitational forces, causing arching and rat-holing in the hopper of dosator capsule filling machines. Static charge accumulation during low-humidity transfer below 30% RH results in measurable weight variability exceeding 3.0% RSD on a Zanasi dosator model with dosing chambers set at 0.50 mL. The powder is therefore unsuitable for direct encapsulation at commercial line speeds above 30,000 capsules/hour. To fill hard gelatin capsules size 0 through 4, the API is first wet-granulated using purified water and PVP K30 at 5.0% w/w binder on a dry basis, then dried in a fluid bed to a loss on drying of 1.5–2.0% w/w. Granule size fraction between 250–600 μm is selected by sieving; oversized particles above 710 μm are re-milled through a 1.0 mm screen, and fines below 180 μm are reintroduced at not more than 15% w/w to avoid dust contamination.

The finished granule is blended with sodium stearyl fumarate 1.0% w/w and colloidal silicon dioxide 0.5% w/w in a bin blender at 12–15 rpm for 20 minutes. Capsule filling is carried out at 30,000–60,000 capsules/hour with periodic weight checks every 15 minutes testing 20 capsules per USP <905>; content uniformity acceptance value must not exceed 15.0. Dissolution testing per USP <711> uses Apparatus 2 (paddle) at 50 rpm in 900 mL of pH 6.8 phosphate buffer; the Q value is not less than 75% at 45 minutes. Accelerated stability at 40 °C / 75% RH per ICH Q1A(R2) reveals that gelatin cross-linking occurs if desiccant quantity is below 1.0 g per 60 mL container volume; HDPE bottles with induction-sealed foil liners and silica gel sachets are therefore mandatory. Terminal product is an oral capsule for companion animal respiratory therapy, with labeled dosing of 2–5 mg active/kg body weight twice daily. Incompatibility is documented with cationic preservatives such as benzalkonium chloride above 0.02% w/v in dissolution media, which artificially retards API release and produces false failures in quality control. Commercial batches must also conform to Ph. Eur. 5.1.4 for microbiological quality of non-sterile products: total aerobic microbial count ≤ 10³ CFU/g and total combined yeasts and moulds ≤ 10² CFU/g.

In drinking water medication for poultry and swine, the API powder is blended with water-soluble diluents to achieve a target final concentration of 100–500 mg/L of drinking water. The API powder typically contains a small fraction of water-insoluble residues below 2.0% w/w; incorporation of polyvinylpyrrolidone K30 at 2.0% w/w as a dispersing agent and sodium carbonate at 1.0% w/w as a pH modifier improves reconstitution in water of hardness up to 250 mg/L CaCO₃ equivalent. Reconstitution time at 25 °C is 90–190 seconds depending on particle size distribution; full dissolution is confirmed visually and by turbidimetry below 10 NTU. Blending is performed in a double-cone blender at 15–20 rpm for 15–20 minutes, followed by passage through a 500 μm sieve to break soft agglomerates. Homogeneity testing per Annex II of Commission Regulation (EC) No 152/2009 requires a coefficient of variation below 5% for ten samples taken from different geometric locations; failure on the first attempt is typically traced to insufficient mixer loading below 50% working volume. Batch-to-batch variation in API particle size D50 from 25 μm to 40 μm alters dissolution time in water by up to 100 seconds, so incoming QC per USP <786> is enforced with acceptance limits D10 > 5 μm, D50 25–45 μm, and D90 < 120 μm. Packaging in multi-layer kraft/aluminum/PE sachets of 500 g and 1 kg protects the moisture-sensitive API; sachet sealing temperature must not exceed 160 °C to avoid localized heat degradation at the seal edge. Storage is specified below 30 °C and below 50% RH. Operational boundaries include hard water above 500 mg/L CaCO₃ equivalent, which causes precipitation of insoluble carbonate salts and reduces bioavailable API by up to 8%; end users must pre-soften water with food-grade citric acid at 0.05% w/v. Terminal product is an oral water-dispersible powder for swine respiratory disease, with a withdrawal period aligned to VICH GL48 residue limits.

Fluid Bed Granulation Moisture Setpoint and Drying Endpoint

Oral granules for incorporation into equine and calf feed require controlled agglomeration of the API with binders to prevent segregation during feed blending operations. Granulation is performed in a top-spray fluid bed granulator such as the Glatt GPCG 60 or equivalent with inlet air temperature set at 55–65 °C and product temperature maintained at 28–32 °C during the spray phase. PVP K30 binder solution at 5.0% w/w concentration is sprayed at a rate of 20–40 g/min per 60 kg batch; atomizing air pressure is set at 2.0–3.0 bar. Bed channeling occurs if inlet air volume falls below 1.5 m³/min per kg of powder charge, resulting in uneven moisture distribution and forming hard, largely insoluble agglomerates above 2.0 mm in diameter. Drying endpoint is determined not by time but by product temperature reaching 45 °C with corresponding outlet air relative humidity below 20%. Loss on drying per USP <731> at 105 °C for 2 hours must fall between 1.5% and 2.5% w/w; values above 3.0% promote microbial proliferation with total aerobic microbial count exceeding 10³ CFU/g per Ph. Eur. 5.1.4, while values below 1.0% cause granule friability above 2.0% as measured by a Roche friabilator at 25 rpm for 100 revolutions. The dried granules are sieved to 16–30 mesh (600–1180 μm). Oversized granules are re-milled, and fines below 250 μm are reintroduced into the subsequent granulation batch at not more than 20% w/w.

Granule dispensing to feed is achieved either as a top dressing at 2.0–5.0 g per 100 kg body weight or as an in-feed admixture at 100–500 mg active per kg complete feed. The terminal granule product is packaged in foil-lined woven polypropylene bags with an inner PE liner; opened bags must be consumed within 28 days because the API absorbs moisture at rates exceeding 0.1% w/w per 24 hours at relative humidity above 60%. Stability data from production-scale batches at 30 °C / 65% RH for 24 months demonstrates API assay retention above 95.0% of label when desiccant bags are added at 2 units per 25 kg package. Limitation: over-drying below 1.0% w/w LOD produces electrostatic surface charge that causes granule adhesion to stainless steel mixer walls, reducing active drug recovery by up to 3% during feed mill transfer.

When Medicated Premix Stability Demands Carrier Selection Above pH 6.5

For large-scale feed mill integration, the API is formulated as a medicated premix at 1.0–5.0% w/w active loading on a carrier system. Carrier selection is driven by chemical compatibility: the API degrades rapidly in acidic microenvironments below pH 5.5, so acidic carriers such as untreated wheat bran at pH 4.8–5.2 are excluded from formulation trials. Ground limestone carriers with pH 8.5–9.5 or sodium bicarbonate-coated corn cob carriers with pH above 7.0 provide the necessary buffering capacity. Carrier oil retention capacity must exceed 12% w/w to permit subsequent liquid binding of the API if a solution-loading step is used. Mixing of the API with the carrier is performed in a horizontal ribbon mixer with a working volume of 500–1000 L at 20–25 rpm for 3–5 minutes after geometric dilution of the active. Homogeneity per Annex II of Commission Regulation (EC) No 152/2009 demands a coefficient of variation below 5% across 10–20 sampling points; failure to meet this threshold on the first mixing attempt is traced to dead zones in the ribbon mixer end plates when operating below 60% working volume. Dust generation during ribbon mixer discharge exceeds 1 mg/m³ occupational exposure guidance when the discharge chute lacks a dust extraction hood; packing stations are equipped with local exhaust ventilation capturing 98% of airborne particles above 0.3 μm.

The premix is then incorporated into complete feed at a ratio from 10–25 kg premix per tonne of finished feed, yielding final API concentrations of 100–500 mg/kg. Thermal stability during feed processing defines the main operational boundary. The API shows unacceptable degradation when steam-conditioning temperatures exceed 70 °C for more than 5 minutes during pelleting; therefore the premix is applied post-pellet via vacuum coating or incorporated into cold pelleting routes below 55 °C. The compliance matrix in the following table summarizes batch release criteria for the medicated premix:

Terminal product is a medicated premix for respiratory disease control in grower-finisher swine. Cleanout validation per current EU GMP requires swab recovery of not less than 70% of spiked API from stainless steel contact surfaces; documented rinse-water testing must show no more than 10 ppm residual API before line changeover to a non-medicated feed product.

When the API is formulated as an oral solution for poultry drinking water systems, solubility enhancement is achieved with a buffered co-solvent system comprising propylene glycol 15–25% v/v, glycerol 5–10% v/v, and purified water to 100%. The API concentration is standardized to 10–25 mg/mL. pH is adjusted to 5.5–6.5 using citric acid/sodium citrate buffer at 0.10 M, which maintains chemical stability and avoids precipitation at pH values below 4.0. Preservative efficacy per USP <51> is achieved with methylparaben 0.18% w/v and propylparaben 0.02% w/v; this system meets Ph. Eur. 5.1.3 acceptance criteria against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis. Manufacturing is performed in stainless steel jacketed vessels with a bottom-mounted high-shear mixer operating at 1200–1500 rpm for 20 minutes; nitrogen sparging reduces dissolved oxygen below 1.0 mg/L before adding sodium metabisulfite at 0.10% w/v as antioxidant. Filtration through 5 μm polypropylene depth filters precedes filling into amber PET bottles to prevent photodegradation at wavelengths below 400 nm. Fill volumes of 100 mL, 250 mL, and 500 mL are calibrated to deliver not less than 100% of labeled volume per USP <698>. In-use stability after first opening is limited to 30 days at 25 °C, after which preservative efficacy drops below the acceptance threshold when challenged with Candida albicans. Sodium metabisulfite is incompatible with sulfite-sensitive animals at residual levels above 0.01% w/v; the label must therefore identify sulfite content in accordance with 21 CFR 201.100(b). The solution is contraindicated in egg-laying hens during the withdrawal period mandated by VICH GL48, typically 7 days for eggs. Terminal product is administered through proportioner dosing pumps calibrated to deliver 0.5–2.0 mL solution per litre of drinking water, with final API concentrations between 10 mg/L and 50 mg/L. Stability studies at 25 °C / 60% RH for 24 months demonstrate assay retention above 97% of label when bottles are stored upright and protected from direct sunlight; horizontal storage during shipping in tropical conditions above 30 °C accelerates API degradation by a factor of 1.8.